Beruflich Dokumente
Kultur Dokumente
21 November 2016
Venue: Royal College of Physicians
lbs.pickevent.com/EN/HealthcareConference2016/
SUBGROUP
One-size-fits-all Different
AVERAGE treatment
treatments SHIFT SUBGROUP
PATIENTS per subgroup
SUBGROUP
(profiles)
• genetic info
• environment
• lifestyle
The potential advantages of Precision Medicine can vary • Subdivision of medicine changes business models of
across areas, but some examples are: pharmaceutical companies from ‘blockbuster’ model to
• Higher effects of medical treatments ‘many-models-small-production’ model
• Medical treatments according to patients’ life plans • New entrants such as biopharma start-ups or IT
companies with capabilities in Big Data analysis and
• Reduced medical expenses by better disease prevention
Artificial intelligence increase roles in Healthcare industry
• Reduced side-effects
• The way local hospitals face patients
Also, the shift to Precision Medicine can have a huge impact fundamentally changes
on each stakeholder in Healthcare industry. Therefore, it is • Data security and privacy protections become a big issue
now indispensable for anyone surrounding this industry to for governments
understand the trends in Precision Medicine and prepare for
the changes triggered by it. We hope you can get deeper insights through
this conference.
DR JANE GRIFFITHS
Company Group Chairman, Janssen EMEA2
Her personal approach focuses on sustainability, past Chairwoman of the Pharmaceutical Research and
accountability, openness and collaboration, and she is leading Manufacturers of America (PhRMA) Europe Committee.
Janssen EMEA to live these values. Jane has held a number Jane is a sponsor of the Johnson & Johnson Global
of senior sales, marketing and research & development Pharmaceuticals Sustainability Council. Jane is also Chair of
positions including International Vice President for Western the Johnson & Johnson Corporate Citizenship Trust in EMEA
Europe and South Africa, and Head of Market Access for and a Board member.
Janssen EMEA.
Completing her PhD in Plant Biochemistry at the University
She is a sponsor for the Women’s Leadership Initiative in of Aberystwyth, UK in 1982, Jane Griffiths started her
Janssen. Other industry roles include past Chairwoman Johnson & Johnson career as a sales representative.
of the European Federation of Pharmaceutical Industries
and Associations (EFPIA) Executive Committee and
John joined Johnson & Johnson in September 2016. In this Dr Mahiben Maruthappu is a London-based doctor and
role John uses his drug discovery and scientific experience to Co-founder of Revere Care, a technology company. He
identify and advance external opportunities in the areas of formerly advised the CEO of NHS England on over £100
Alzheimer’s Disease and Mood Disorders. billion of health spending, and established the NHS
Innovation Accelerator which benefitted 3 million people in 6
Prior to joining Johnson & Johnson, since November
months, signing 380 deals in its first year.
2014, John was Head of Neuroscience and Mental Health
at the Wellcome Trust. Previous to that he worked at Eli He has advised a range of organisations, from startups to
Lilly and Company at their neuroscience research campus multilaterals, including the Swiss government, the Experiment
near London, UK. At Lilly he led a team of labs dedicated Fund and the WHO. Maruthappu has a strong interest in
to identifying new therapies for Alzheimer’s disease and research with over 100 peer-reviewed publications and 50
schizophrenia. academic awards. His work has been featured by BBC News
and the international press.
John’s scientific interests centre on synaptic mechanisms in
circuit function, and how dysfunction causes psychiatric and He is Chairman of the UK Medical Students’ Association
neurological disease. John obtained a BSc in Pharmacology (UKMSA), and has authored three medical books.
and Biochemistry at the University of Southampton in Maruthappu was educated at Oxford, Cambridge and
1990 and remained at Southampton for his graduate work, Harvard universities; he was the first person from British
studying mechanisms of epilepsy with Prof Howard Wheal. healthcare to be included in Forbes’ 30 under 30, and
recently ranked amongst the 100 most influential leaders in
In 1994 he joined Dr Robert Malenka’s laboratory
health technology, globally.
at University of California San Francisco working on
mechanisms of long-term synaptic plasticity in hippocampus
and somatosensory cortex, also in close collaboration with
Dr Roger Nicoll. After completion of this post doc position,
John joined Prof Graham Collingridge’s laboratory at the
University of Bristol back in the UK in 1996, where he
completed a one year post doc before establishing his own
lab there. He rose up through the ranks to full Professor
before leaving in 2004 to set up a lab at the Intramural
Program at NINDS / NIH in Bethesda, MD, USA studying
mechanisms and roles of synaptic plasticity in developing
cortical circuits.
With over 20 years of consulting experience, Jerry focuses Blanca Rosales Baez graduated in 1998 with honours from
on digital transformation, growth strategy, R&D and resource a B.A. in International Trade from a top Latin-American
allocation for life sciences clients. He is trusted advisor University in Mexico City and University of Massachusetts.
across pharma, biotech, and consumer health sectors, She then held various roles in different industries:
advising leaders on their most critical decisions – Competitive Intelligence in EPC for Oil & Gas; International
to enter new sectors, diversify product offerings, or realign Tax Consultant with PricewaterhouseCoopers, Strategic
commercial models for success in value-based markets. Advisor to the Presidency of Mexico.
Jerry has led major transformations of portfolio management Pursuant to this, she moved to London and in 2004
and R&D decision making processes for six of the top 12 completed a full-time MBA at London Business School.
global pharmas and he has written and spoken extensively on She graduated with specializations in Entrepreneurship,
the topic of portfolio strategy. In recent work, he developed Strategy and Analytical Marketing. During the MBA, Blanca
a patient-centered solution architecture (e.g., digital patient attained experience in the FMCG industry through a summer
& HCP engagement), to accelerate deployment of new internship, a shadowing and a 2nd -year project.
solution innovation for a mid-sized specialty pharma. Also,
Upon graduation from the MBA, Blanca moved to
for a leading digital health services company, he created
Switzerland where she served across various commercial
a strategy to enter patient-support services, defining a
roles within Novartis’ global headquarters and later Novartis
36-month growth and M&A playbook helping clients align
UK country organization. These span across different
scientific and commercial strategy with patient-centered,
commercial functions in different parts of Pharma’s value
value based markets. Jerry has broad experience across
chain, as well as sundry therapeutic and disease areas.
disease categories, with particular depth in oncology and
immunology. He has worked across clinical, regulatory, and In the latest years she became Head of New Products
commercial organizations and in most major geographies – Portfolio for Mundipharma (EU headquarters), and has now
the U.S., major Europe, and primary emerging markets. ventured herself in transitioning her career towards the
entrepreneurial healthtech scene.
MICHAEL THOMAS
Partner, Global
His clients have included AstraZeneca, Bayer, EliLilly, Gilead, Other areas of consulting focus include: Organisational
GlaxoSmithKline, Johnson&Johnson, Novartis, Pfizer, Pliva design and performance management; Direct to Patient
/ Teva, Sanofi, Schering-Plough, Shire and Takeda and marketing; and Customer Relationship Management (CRM),
pharmaceutical industry associations in Europe and US. both as a business strategy and technology issue, and its
application to pharmaceutical sales and marketing. He has
His current area of interest is in examining the opportunities
advised a number of Top 10 players on their European and
that the pharmaceutical industry has to partner with
global strategies. He has contributed to many industry
healthcare providers to improve access and returns on
articles and is a frequent conference speaker.
innovation. Most recently he has advised and helped
innovation-based players assess the commercial and Before joining AT Kearney, Michael was EMEA leader for
organisational models required for success in the current Sales & Marketing in the pharmaceutical practices of IBM
market access environment. He has also advised companies and PwC Consulting. He has held a senior management
on how to support an ageing portfolio, particularly around position in Strategy and Planning with SmithklineBeecham,
more commercial approaches to channel management and before entering consultancy ran a PR agency specialising
to drive growth late in product lifecycles in the light of in lifestyle products.
increased generic competition. Michael is a leading expert on
value pricing in the pharmaceutical industry, helping clients
develop novel pricing and value approaches as low-cost
generics become the key comparator for new products.
More broadly he has helped the Industry in negotiations
with Government on issues relating to industrial strategy,
healthcare reform and pricing and re-imbursement.
Junaid Bajwa is a practicing GP in the NHS, and the Rabin is an accomplished digital executive. He was
Executive Director of Healthcare Services for MSD (UK). responsible for DoubleClick’s Media business globally,
ran Strategic Partnerships for Google in EMEA and
Junaid qualified as a GP in 2009 and has since gone on to
was President & COO of research engine FindTheBest,
undertake a number of roles within the NHS spanning the
where he ran strategy, operations, sales, marketing and
payer, provider, regulator and public health space. He has had
business development.
responsibilities in leading on Physical Health, Mental Health,
IT, & Integrated Care projects. In 2014, he was seconded
onto the NHS Leadership Academy Fast Track Executive
Programme, where he was appointed as the Redesign
Director of a large Integrated Mental Health & Community
Foundation Trust, and reviewed global health systems on
behalf of the NHS to drive quality improvement within the
Service. Thereafter, he was seconded to NHS England as a
Clinical Associate on the New Models of Care Programme.
Junaid lives in London with his wife and two young children,
and his hobbies include playing tennis, basketball and cricket.
10
Jackie Hunter is the Chief Executive Officer of Benevolent Roy Katso’s responsibilities in the Bioelectronics R&D
Bio. Benevolent Bio unites traditional pharmaceutical Unit include identifying the best talent wherever it exits
development methodology with Artificial Intelligence to in the world and building new ecosystems in partnership
augment the research capabilities of its drug scientists so with academics, technology companies, funding agencies
that they can gain new insights to increase the efficiency and philanthropic organisations in order to accelerate the
of medicines development. realisation of the delivery of the potential of Bioelectronic
Medicines. This is done through an Open Innovation ethos
Jackie has over thirty years of experience in the
and building partnerships that are multi-disciplinary in
bioscience research sector, working across academia and
nature, co-exist in a complementary manner, and share
industry including leading neurology and gastrointestinal
a common vision of expediting delivering this treatment
drug discovery and early clinical development for
modality to address unmet patient need. An example of this
GlaxoSmithKline. She founded OI Pharma Partners in 2010
is the Innovation Challenge where Roy isaccountable for
to support the life science sector in harnessing the power of
the identification and creation of global multi-disciplinary
open innovation and most recently was Chief Executive of
teams to undertake the development of an open access
the Biotechnology and Biological Sciences Research Council.
research platform with the ability to read, write and erase
She holds a personal chair from St George’s Hospital Medical
the neuronal language in visceral organs of interest. Such
School, which was awarded in recognition of her contribution
a common platform not only solves a major hurdle for
to bioscience research. In 2010 she was awarded a CBE
the bioelectronic medicine research community, but also
in the Queen’s Birthday Honours list for Services to the
accelerates the technology development that may go into
Pharmaceutical Industry.
future manifestations of therapeutic devices that will be at
the centre of new ventures and partnerships.
11
Chris Meier is a Principal in the London office of the Boston Professor Joanne Hackett is the Chief Commercial Officer
Consulting Group, having joined BCG in 2012. Chris is a core at the Precision Medicine Catapult (PMC). She has been
member of the firm’s Healthcare practice area, and is one of actively involved in clinical research for over 15 years
the leaders of BCG’s scientist network. in Canada, America, Germany, Sweden and the UK. An
accomplished entrepreneur, scientist and strategist, she has
Chris has worked intensively with clients in the pharma,
experience in the execution and management of complex
biotech, medtech, mainly in the US and Europe. He
business transactions, as well as broad business development
has significant experience across pharmaceutical R&D,
experience in negotiation, execution and management of
innovation, operations and commercial.
hundreds of transactions with pharma, biotech, academia
In the digital space, Chris has supported many and non-profit organisations. Her expertise in creating
pharmaceutical clients across a broad range of topics, connections between industry, academia and the NHS will
including digital development, data integration, and the help inform solutions the PMC are currently tackling and
use of big data approaches in R&D. Chris has also helped support the growth of the UK Precision Medicine industry.
pharmaceutical companies develop precision medicine
The PMC is innovating to build a world-leading, UK-based,
strategies, including biomarker discovery and development,
Precision Medicine industry. It is establishing this at pace
and the integration of therapeutics with diagnostics.
and scale so that it is safe, reliable and efficient in delivering
Prior to joining BCG, Chris was Principal Scientist at UCB, targeted treatments to meet patients’ personalised needs, at
a biopharmaceutical company. In his industrial work he an affordable cost. The PMC is headquartered in Cambridge,
contributed to the discovery of several drug candidates in with national and regional Centres of Excellence across the
autoimmune diseases and oncology. Chris holds a PhD in UK. Working with companies, charities, academia, policy
Biophysics from Oxford University, and an MBA from London makers, hospitals, patient groups and healthcare authorities
Business School (Class of 2012). in these clusters and internationally, it will provide the
leadership to grow the industry while delivering local health
care impact.
12
Key dates
• Kick-off event and Commencement of team registration beginning of February
• One or more physical mixer events will be also held to facilitate face-to-face
interaction between participants in mid-February
• First-round submission: March – end of March
• Announcement on finalists: mid-April
• Final presentation: May – end of May at London Business School
13
A.T. Kearney is a leading global management consulting firm with offices in more than 40
countries. At A.T. Kearney, we work together to provide every colleague with full and ready
access to the best of our firm to help you quickly achieve your full potential. We promise
immediate impact and growing advantage to our clients – and that same promise rings true
for our people. You will have an opportunity to contribute to client outcomes from day one.
Because we value collaboration, you will work with team members who will help you grow as
you help our clients solve their most mission-critical issues.
Conference Committee
fo
14
www.jnj.com/careers @JNJUniversity
Johnson & Johnson Services, Inc. is a member of the Johnson & Johnson Family of Companies. © Johnson & Johnson Services, Inc. 2016. Johnson &
Johnson companies are equal opportunity employers
Who we are
How we do it
Transforming the way we work to better meet patient
needs
At GSK, we believe how we do business is as important as what we do – it’s
what makes us different - so we are challenging industry norms by
changing the way we work.
Why we do it
We know growing a sustainable business that develops innovative
pharmaceutical medicines, vaccines and consumer healthcare products is
critical to help us continue to tackle global healthcare challenges.
We have created a way of working that harnesses our scientific expertise, collaborative approach,
partnerships and global reach – to meet patient and consumer needs and deliver returns to our
shareholders.